Company Registration No. 06742160 (England and Wales)
WALTERS MEDICAL LIMITED
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
PAGES FOR FILING WITH REGISTRAR
LB GROUP
The Octagon Suite E2
2nd Floor Middleborough
Colchester
Essex
CO1 1TG
WALTERS MEDICAL LIMITED
CONTENTS
Page
Statement of financial position
1 - 2
Notes to the financial statements
3 - 8
WALTERS MEDICAL LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2023
31 December 2023
- 1 -
2023
2022
Notes
£
£
£
£
Fixed assets
Tangible assets
4
740,671
321,235
Investments
5
100
100
740,771
321,335
Current assets
Stocks
1,446,246
1,314,493
Debtors
6
1,185,090
1,299,361
Cash at bank and in hand
354,097
539,851
2,985,433
3,153,705
Creditors: amounts falling due within one year
7
(968,783)
(962,816)
Net current assets
2,016,650
2,190,889
Total assets less current liabilities
2,757,421
2,512,224
Creditors: amounts falling due after more than one year
8
(108,743)
(126,728)
Provisions for liabilities
(146,540)
(65,448)
Net assets
2,502,138
2,320,048
Capital and reserves
Called up share capital
1,850
1,850
Profit and loss reserves
2,500,288
2,318,198
Total equity
2,502,138
2,320,048

The directors of the company have elected not to include a copy of the income statement within the financial statements.true

For the financial year ended 31 December 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

WALTERS MEDICAL LIMITED
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 DECEMBER 2023
31 December 2023
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 19 September 2024 and are signed on its behalf by:
Mr R L Walters
Director
Company Registration No. 06742160
WALTERS MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
- 3 -
1
Accounting policies
Company information

Walters Medical Limited is a private company limited by shares incorporated in England and Wales. The registered office is The Octagon Suite E2, 2nd Floor Middleborough, Colchester, Essex, CO1 1TG.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

1.4
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold Improvements
Over 10 years
Plant and machinery
25% Reducing balance
Equipment
25% Reducing balance
Motor vehicles
25% Reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

WALTERS MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023
1
Accounting policies
(Continued)
- 4 -
1.6
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

1.7
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.8
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.9
Cash at bank and in hand

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.10
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

WALTERS MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023
1
Accounting policies
(Continued)
- 5 -
1.11
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.12
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

1.13
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.14
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.15
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.16
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

1.17

Employee benefit trusts

The Company has created a trust whose beneficiaries will include employees of the Company and their dependents. Assets held under this trust will be controlled by trustees who will be acting independently and entirely at their own discretion.

 

Where assets are held in the trust and these are considered by the Company to be in respect of services already provided by employees to the Company, the Company will account for these as assets of the trust when payment is made to the trust. The value transferred will be charged in the Company's profit and loss account for the year to which it relates.

WALTERS MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023
- 6 -
2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2023
2022
Number
Number
Total
17
17
4
Tangible fixed assets
Land and buildings
Plant and machinery etc
Total
£
£
£
Cost
At 1 January 2023
276,199
454,972
731,171
Additions
471,594
16,006
487,600
At 31 December 2023
747,793
470,978
1,218,771
Depreciation and impairment
At 1 January 2023
93,220
316,716
409,936
Depreciation charged in the year
32,009
36,155
68,164
At 31 December 2023
125,229
352,871
478,100
Carrying amount
At 31 December 2023
622,564
118,107
740,671
At 31 December 2022
182,979
138,256
321,235
5
Fixed asset investments
2023
2022
£
£
Shares in group undertakings and participating interests
100
100
WALTERS MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023
- 7 -
6
Debtors
2023
2022
Amounts falling due within one year:
£
£
Trade debtors
546,648
612,916
Amounts owed by group undertakings
585,464
613,608
Other debtors
52,978
72,837
1,185,090
1,299,361
7
Creditors: amounts falling due within one year
2023
2022
£
£
Bank loans
19,202
18,573
Trade creditors
514,065
248,905
Amounts owed to group undertakings
27,788
45,141
Corporation tax
65,543
214,601
Other taxation and social security
192,340
236,032
Other creditors
149,845
199,564
968,783
962,816

Bank loans are secured by a Mortgage Debenture dated 5 October 2010 incorporating a fixed and floating charge over all current and future assets of a company.

8
Creditors: amounts falling due after more than one year
2023
2022
£
£
Bank loans and overdrafts
108,743
126,728

Bank loans are secured by a Mortgage Debenture dated 5 October 2010 incorporating a fixed and floating charge over all current and future assets of a company.

Creditors which fall due after five years are as follows:
2023
2022
£
£
Payable by instalments
24,719
46,661
WALTERS MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023
- 8 -
9
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2023
2022
£
£
48,929
51,135
10
Directors' transactions

No guarantees have been given or received.

2023-12-312023-01-01false19 September 2024CCH SoftwareCCH Accounts Production 2024.200No description of principal activityMrs J S RhodesMr R L Waltersfalsefalse067421602023-01-012023-12-31067421602023-12-31067421602022-12-3106742160core:LandBuildings2023-12-3106742160core:OtherPropertyPlantEquipment2023-12-3106742160core:LandBuildings2022-12-3106742160core:OtherPropertyPlantEquipment2022-12-3106742160core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3106742160core:CurrentFinancialInstrumentscore:WithinOneYear2022-12-3106742160core:Non-currentFinancialInstrumentscore:AfterOneYear2023-12-3106742160core:Non-currentFinancialInstrumentscore:AfterOneYear2022-12-3106742160core:CurrentFinancialInstruments2023-12-3106742160core:CurrentFinancialInstruments2022-12-3106742160core:ShareCapital2023-12-3106742160core:ShareCapital2022-12-3106742160core:RetainedEarningsAccumulatedLosses2023-12-3106742160core:RetainedEarningsAccumulatedLosses2022-12-3106742160bus:Director22023-01-012023-12-3106742160core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-01-012023-12-3106742160core:PlantMachinery2023-01-012023-12-3106742160core:FurnitureFittings2023-01-012023-12-3106742160core:MotorVehicles2023-01-012023-12-31067421602022-01-012022-12-3106742160core:LandBuildings2022-12-3106742160core:OtherPropertyPlantEquipment2022-12-31067421602022-12-3106742160core:LandBuildings2023-01-012023-12-3106742160core:OtherPropertyPlantEquipment2023-01-012023-12-3106742160core:WithinOneYear2023-12-3106742160core:WithinOneYear2022-12-3106742160core:Non-currentFinancialInstruments2023-12-3106742160core:Non-currentFinancialInstruments2022-12-3106742160bus:PrivateLimitedCompanyLtd2023-01-012023-12-3106742160bus:SmallCompaniesRegimeForAccounts2023-01-012023-12-3106742160bus:FRS1022023-01-012023-12-3106742160bus:AuditExemptWithAccountantsReport2023-01-012023-12-3106742160bus:Director12023-01-012023-12-3106742160bus:FullAccounts2023-01-012023-12-31xbrli:purexbrli:sharesiso4217:GBP